share_log

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K:重大事件
美股SEC公告 ·  08/15 09:27

Moomoo AI 已提取核心信息

On August 15, 2024, Mangoceuticals, Inc., also known as MangoRx, reported substantial growth in its financial results for the first half of 2024. The company, which specializes in men's health and wellness products, including treatments for erectile dysfunction, hair growth, weight loss, and hormone replacement therapies, disclosed a 1,685% increase in shareholders' equity and a 56% increase in year-over-year revenue. Shareholders' equity surged to $13.8 million, up from $774,754 at the end of the previous year, largely due to the acquisition of a patent portfolio from Intramont Technologies. Revenue for the six months ended June 30, 2024, reached $377,258, with a gross profit of $217,190, marking significant growth from the same period in the previous year. CEO Jacob Cohen highlighted the company's focus on innovation and customer...Show More
On August 15, 2024, Mangoceuticals, Inc., also known as MangoRx, reported substantial growth in its financial results for the first half of 2024. The company, which specializes in men's health and wellness products, including treatments for erectile dysfunction, hair growth, weight loss, and hormone replacement therapies, disclosed a 1,685% increase in shareholders' equity and a 56% increase in year-over-year revenue. Shareholders' equity surged to $13.8 million, up from $774,754 at the end of the previous year, largely due to the acquisition of a patent portfolio from Intramont Technologies. Revenue for the six months ended June 30, 2024, reached $377,258, with a gross profit of $217,190, marking significant growth from the same period in the previous year. CEO Jacob Cohen highlighted the company's focus on innovation and customer satisfaction, with expectations for continued growth in the latter half of the year. MangoRx is also preparing to launch new products, including compounded oral dissolvable tablet (ODT) GLP-1 inhibitors for weight loss and a hormone therapy product for low testosterone. The company's telemedicine platform facilitates the prescription and delivery of its products directly to consumers.
2024年8月15日,Mangoceuticals,Inc.(也称为MangoRx)报告了2024年上半年财务结果的显著增长。该公司专门从事男性健康和健康产品,包括治疗勃起功能障碍,促进头发生长,减轻体重和激素替代疗法的治疗,披露股东权益增长1685%,同比营业收入增长56%。股东权益大幅飙升至1380万美元,比上年底的774,754美元高,主要是由于从Intramont Technologies收购了一个专利组合。截至2024年6月30日的六个月的营业收入达到了377,258美元,毛利润为217,190美元,与去年同期相比实现了显着增长。首席执行官Jacob Cohen强调了公司的创新和客户满意度,并期望在后半年继续增长。MangoRx还准备推出新产品,包括用于减重的复合口服可溶性片剂(ODT)GLP-1抑制剂和用于低睾丸素的激素疗法产品。该公司的远程医疗平台可以直接向消费者开具处方并交付其产品。
2024年8月15日,Mangoceuticals,Inc.(也称为MangoRx)报告了2024年上半年财务结果的显著增长。该公司专门从事男性健康和健康产品,包括治疗勃起功能障碍,促进头发生长,减轻体重和激素替代疗法的治疗,披露股东权益增长1685%,同比营业收入增长56%。股东权益大幅飙升至1380万美元,比上年底的774,754美元高,主要是由于从Intramont Technologies收购了一个专利组合。截至2024年6月30日的六个月的营业收入达到了377,258美元,毛利润为217,190美元,与去年同期相比实现了显着增长。首席执行官Jacob Cohen强调了公司的创新和客户满意度,并期望在后半年继续增长。MangoRx还准备推出新产品,包括用于减重的复合口服可溶性片剂(ODT)GLP-1抑制剂和用于低睾丸素的激素疗法产品。该公司的远程医疗平台可以直接向消费者开具处方并交付其产品。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息